🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "huge turning point" in the effort against drug-resistant strains of the infection, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are increasing worldwide, with data suggesting in excess of 82 million infections each year. Particularly high rates are seen in the African continent and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely advancement in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce therapeutic options at this time.”

Public health authorities are increasingly worried about the surge in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". A tracking program found that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Approval

Zoliflodacin, marketed under the name a brand name, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts anticipate that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in concurrent days. This treatment, which is additionally indicated for UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This milestone represents a significant shift in the management of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Research Study Results and Global Access

According to results released by a major medical journal, the new drug successfully treated the vast majority of uncomplicated infections. This places it at an equal footing with the typical regimen, which uses an injection and a pill. The research enrolled nearly 1,000 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the ability to license and sell the drug in a wide range of regions with limited resources.

Medical professionals treating patients have expressed optimism. Having a easy-to-administer therapy such as this is seen as a "revolutionary step" for public health efforts. This is considered essential to reduce the burden of the disease for people and to halt the transmission of highly drug-resistant gonorrhoea worldwide.